IDEAYA Biosciences enrolls first patient in clinical combination trial
IDEAYA Biosciences (NASDAQ:IDYA) enrolled the first patient in its Phase 1/2 clinical trial evaluating the combination of its drug candidates, IDE892 and IDE397, in patients with MTAP-deleted solid tumors.










